DSGN stock icon

Design Therapeutics
DSGN

$3.38
2.07%
 

About: Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Employees: 57

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

47% more capital invested

Capital invested by funds: $84M [Q4 2023] → $124M (+$39.8M) [Q1 2024]

36% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 14

6% more funds holding

Funds holding: 88 [Q4 2023] → 93 (+5) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

2.24% less ownership

Funds ownership: 56.64% [Q4 2023] → 54.39% (-2.24%) [Q1 2024]

43% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 37

78% less call options, than puts

Call options by funds: $4K | Put options by funds: $18K

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$4
18%
upside
Avg. target
$7
107%
upside
High target
$12
255%
upside

3 analyst ratings

positive
33%
neutral
67%
negative
0%
Piper Sandler
Yasmeen Rahimi
255%upside
$12
Overweight
Upgraded
7 May 2024
RBC Capital
Leonid Timashev
18%upside
$4
Sector Perform
Reiterated
20 Mar 2024
Wedbush
Laura Chico
48%upside
$5
Neutral
Reiterated
20 Mar 2024

Financial journalist opinion